Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

United States

The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Memorial Sloan Kettering Cancer Center, New York, New York

Huntsman Cancer Institute, Salt Lake City, Utah

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin